Author： Berkovic D.
Publisher： Elsevier
ISSN： 0306-3623
Source： General Pharmacology, Vol.31, Iss.4, 1998-10, pp. : 511-517
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Drug Resistance to Cytotoxic Nucleoside Analogues
Current Drug Targets, Vol. 4, Iss. 6, 2003-08 ,pp. :
Access to resources
Recommend
Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry, Vol. 16, Iss. 32, 2009-11 ,pp. :
Antibody therapy phase I trial safety remains topical
Reactions Weekly, Vol. 1, Iss. 1121, 2006-01 ,pp. :
Phase I oncology trials: risks and benefits vary by trial type
Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. :
Antibody therapy phase I trial safety remains topical
Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. :